SCHEMBL22734263

SCHEMBL22734263

Cc1ccc2c(C[C@H](NC(=O)OC(C)(C)C)C(=O)O)c[nH]c2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.69
MAPT P10636 2/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
ACE P12821 3/20 0.62
TACR1 P25103 2/20 0.60
CTSL P07711 2/20 0.57
CTSS P25774 1/20 0.57
CTSK P43235 1/20 0.57
KDM4E B2RXH2 1/20 0.55
P2RY14 Q15391 1/20 0.54
TP53 P04637 2/20 0.52
ADAM17 P78536 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
POLB P06746 1/20 0.49
SSTR3 P32745 1/20 0.48
ITGB2 P05107 1/20 0.48
ICAM1 P05362 1/20 0.48
ITGAL P20701 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22734264 1.00 SCN9A (0.69) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL29842668 1.00 SCN9A (0.69) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL8208133 0.91 MAPT (0.63) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL22091571 0.89 SCN9A (0.69) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL22091572 0.89 SCN9A (0.69) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL23051916 0.88 SCN9A (0.68) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL8502043 0.88 SCN9A (0.68) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL31407325 0.88 SCN9A (0.68) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL3014096 0.88 SCN9A (0.68) SCN9AMAPTSMN1; SMN2ACETACR1
SCHEMBL31407544 0.88 SCN9A (0.68) SCN9AMAPTSMN1; SMN2ACETACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF TECHNION RES & DEV FOUNDATION (IL) 2025-10-23 US disclosed
US-20240057599-A1 METHODS FOR IMPROVING FRUIT QUALITY THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) 2024-02-22 US disclosed
CN-117062529-A Method for improving fruit quality 以色列农业和农村发展部农业研究组织(范卡尼研究所) 2023-11-14 CN disclosed
US-20230330064-A1 TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE RAMBAM MED-TECH LTD. (IL) 2023-10-19 US disclosed
CN-115843565-A Method for improving plant performance 以色列农业和农村发展部农业研究组织(范卡尼中心) 2023-03-28 CN disclosed
CN-111988994-B Method for improving plant performance 以色列农业和农村发展部农业研究组织(范卡尼中心) 2023-01-10 CN disclosed
US-20200383327-A1 METHOD OF IMPROVING PLANT PERFORMANCE THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) 2020-12-10 US disclosed
CN-111988994-A Method for improving plant performance 以色列农业和农村发展部农业研究组织(范卡尼中心) 2020-11-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330064-A1 TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE RPTOR, PSMG3, MTOR SCN9A 4655/4885MAPT 1195/4885SMN1; SMN2 2185/4885
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF PSMC1, PSME3, PSMA6 SCN9A 3990/4885MAPT 1802/4885SMN1; SMN2 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.